NewAmsterdam Pharma Co NV (FRA:KH6) ROCE % : -23.52% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NewAmsterdam Pharma Co NV's annualized ROCE % for the quarter that ended in Sep. 2024 was -23.52%.

NewAmsterdam Pharma Co NV ROCE % Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV ROCE % Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-157.88

-9.02

-47.01

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial							-41.69	-68.64	-60.24	-49.78	-23.52

NewAmsterdam Pharma Co NV ROCE % Calculation

NewAmsterdam Pharma Co NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-162.226	/	( ( (451.701 - 34.038)	+	(318.288 - 45.756) )	/ 2 )
	=	-162.226	/	( (417.663	+	272.532)	/ 2 )
	=	-162.226	/	345.0975
	=	-47.01 %

NewAmsterdam Pharma Co NV's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-86.02	/	( ( (414.975 - 42.09)	+	(395.711 - 37.171) )	/ 2 )
	=	-86.02	/	( ( 372.885	+	358.54 )	/ 2 )
	=	-86.02	/	365.7125
	=	-23.52 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

NewAmsterdam Pharma Co NV (FRA:KH6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NewAmsterdam Pharma Co NV ROCE % Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NAMS:USA KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Co NV Headlines

No Headlines